Search

US-12618842-B2 - Cancer test method

US12618842B2US 12618842 B2US12618842 B2US 12618842B2US-12618842-B2

Abstract

The present invention relates to a method for analyzing a biological sample obtained from a subject, comprising analyzing components contained in a biological sample by an assay using a first molecule selected from the group consisting of a molecule binding to a sugar chain bindable with BC2LCN, a molecule binding to SerpinA3, and a molecule binding to Gal3BP, and a second molecule that is BC2LCN.

Inventors

  • Hiroaki Tateno
  • Tatsuya Oda
  • Osamu Shimomura

Assignees

  • NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY
  • UNIVERSITY OF TSUKUBA

Dates

Publication Date
20260505
Application Date
20220411
Priority Date
20191011

Claims (4)

  1. 1 . A method for detecting components in a biological sample obtained from a subject, comprising: contacting the sample with a first molecule that is an antibody binding to SerpinA3 or an antibody binding to Gal3BP, and with a second molecule that is BC2LCN, and detecting binding of the first and second molecules to the components in the sample.
  2. 2 . The method according to claim 1 , wherein the subject has a cancer or has a potential to have the cancer.
  3. 3 . The method according to claim 2 , wherein the subject has a pancreatic cancer or has a potential to have the pancreatic cancer.
  4. 4 . The method according to claim 3 , wherein the subject has a stage I or II pancreatic cancer or has a potential to have the stage I or II pancreatic cancer.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS This application is a Continuation of PCT International Application No. PCT/JP2020/038300, filed on Oct. 9, 2020, which claims priority under 35 U.S.C. § 119(a) to Japanese Patent Application No. 2019-187197, filed on Oct. 11, 2019. Each of the application(s) is hereby expressly incorporated by reference, in its entirety, into the present application. TECHNICAL FIELD The present invention relates to a cancer test method and a test kit for the same. BACKGROUND ART BC2LCN is a glycoprotein, that is, a kind of lectin, and according to previous reports, it has been revealed that BC2LCN has affinity for glycoprotein sugar chains H-type 1 (Fucα1-2Galβ1-3GlcNAc) and H-type 3 (Fucα1-2Galβ1-3GalNAc), and can thus be used as a probe for detecting an undifferentiated marker of human ES cells or iPS cells that express a podocalyxin having an H-type 3 sugar chain (Patent Literature 1). In addition, according to previous reports, it has been revealed that BC2LCN strongly binds to a cancer tissue and can thus be used as a probe for detecting a cancer marker (Patent Literature 2). According to Patent Literature 2, the presence of a protein recognized by BC2LCN and keratan sulfate in blood components of some cancer patients have been confirmed by a sandwich assay with BC2LCN and an antibody binding to keratan sulfate. SerpinA3 is also referred to as an α1-antichymotrypsin and is known to be associated with diseases such as some tumors. SerpinA3 has been developed as a blood test marker (Non-Patent Literature 1). Gal3BP is also referred to as LGAL3SBP or MAC-2-BP, and is found at high concentrations in the sera of patients with a breast cancer, a lung cancer, a rectal colorectal cancer, an ovarian cancer, and an endometrial cancer (Non-Patent Literature 2). CITATION LIST Patent Literature Patent Literature 1: WO2014/126146APatent Literature 2: WO2017/061449A Non-Patent Literature Non-Patent Literature 1: Nie, S. et al., J. Proteome Res. 13: 1873-1884, 2014Non-Patent Literature 2: Koths, K. et al., J. Biol. Chem. 268: 14245-14249, 1993 SUMMARY OF INVENTION The present invention relates to a cancer test method and a test kit for the same. According to the present invention, the following inventions are provided. (1) A method for analyzing a blood sample obtained from a subject, comprising: analyzing a blood component contained in a blood sample by a sandwich assay or an immunochromatographic assay, using a first molecule selected from the group consisting of BC2LCN, an antibody binding to SerpinA3, and an antibody binding to Gal3BP, and a second molecule that is BC2LCN. (2) The method as described in (1), in which the first molecule is an antibody binding to SerpinA3. (3) The method as described in (1), in which the first molecule is an antibody binding to Gal3BP. (4) The method as described in (1), in which the first molecule is BC2LCN. (5) The method as described in any one of (1) to (4), in which the subject has a cancer or has a potential to have the cancer. (6) The method as described in (5), in which the subject has a pancreatic cancer or has a potential to have the pancreatic cancer. (7) The method as described in (6), in which the subject has a stage I or II pancreatic cancer or has a potential to have the stage I or II pancreatic cancer. (8) A kit for a sandwich assay or an immunochromatographic assay, comprising a first molecule selected from the group consisting of BC2LCN, an antibody binding to SerpinA3, and an antibody binding to Gal3BP, and a second molecule that is BC2LCN, in which the kit can be used to measure an amount of a glycoprotein in a blood sample of a subject, using the first molecule and the second molecule. (9) The kit as described in (8), in which the first molecule is an antibody binding to SerpinA3 and a protein portion of the glycoprotein is SerpinA3. (10) The kit as described in (8), in which the first molecule is an antibody binding to Gal3BP and a protein portion of the glycoprotein is Gal3BP. (11) The kit as described in (8), comprising: a second molecule that is immobilized BC2LCN; anda first labeled molecule selected from the group consisting of labeled BC2LCN, an antibody binding to labeled SerpinA3, and an antibody binding to labeled Gal3BP. (12) The kit as described in any one of (8) to (11), in which the kit is used for detecting a cancer. (13) The kit as described in (12), in which the cancer is a cancer selected from the group consisting of a pancreatic cancer and a colorectal cancer. (14) The kit as described in (13), in which the cancer is a stage I or II pancreatic cancer. (15) A method for predicting whether or not a subject is a cancer, comprising carrying out the method as described in (1) to (7). (16) A method for analyzing a blood sample obtained from a subject, comprising: analyzing the presence or absence or the concentration of a blood component in a blood sample,in which the blood component is a component selected from the group con